You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和黃醫藥與君實生物(01877.HK)在中國啟動腫瘤聯合療法二期臨床試驗
阿思達克 01-13 16:50

和黃醫藥公布,旗下產品「索凡替尼」與君實生物(01877.HK)的PD-1單克隆抗體「拓益」,聯合於中國啟動治療晚期實體瘤患者的II期臨床試驗。

該公司指,是次臨床試驗是雙方全球合作的一部分,旨在測試兩項產品的聯合療法同時針對腫瘤微環境中多種細胞類型和信號通路的協同抗腫瘤作用。

「索凡替尼」為一款口服抗血管生成免疫逃逸激(酉每)抑製劑,作為非胰腺神經內分泌瘤的新藥上市申請已於去年底獲中國國家藥監局藥品審評中心納入優先審評,並被美國食品藥品監督管理局授予孤兒藥資格,用於治療胰腺神經內分泌瘤。而「拓益」已於2018年獲國家藥監局批准上市。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account